Search research articles
Contact Us
Filters
Showing results (11-20 of 49) with videos related to
Page
of 5
Sort By:
Expert Reviews in Molecular Medicine
|
September 25, 2004
Tumour-targeted drug and gene delivery: principles and concepts
Jim Cassidy, Andreas G Schätzlein
Expert Review of Gastroenterology & Hepatology
|
February 12, 2011
XELOX in colorectal cancer: a convenient option for the future?
Colin R Lindsay, Jim Cassidy
Seminars in Oncology
|
November 8, 2002
Oxaliplatin-related side effects: characteristics and management
Jim Cassidy, Jean-Louis Misset
Drugs
|
September 16, 2005
Adjuvant treatment strategies for early colon cancer
Ashita M Waterston, Jim Cassidy
Trials
|
April 1, 2009
The second Symptom Management Research Trial in Oncology (SMaRT Oncology-2): a randomised trial to determine the effectiveness and cost-effectiveness of adding a complex intervention for major depressive disorder to usual care for cancer patients
Jane Walker, Jim Cassidy, Michael Sharpe, et al.
Expert Opinion on Emerging Drugs
|
November 13, 2003
Emerging drugs in colorectal cancer
Lucy Scott, Judith Fraser, Jim Cassidy
Trials
|
October 2, 2009
The third symptom management research trial in oncology (SMaRT oncology-3): a randomised trial to determine the efficacy of adding a complex intervention for major depressive disorder (depression care for people with lung cancer) to usual care, compared to usual care alone in patients with lung cancer
Jane Walker, Jim Cassidy, Michael Sharpe, et al.
Cancer Treatment Reviews
|
February 15, 2005
Liver metastases from breast cancer: management of patients with significant liver dysfunction
Max S Mano, Jim Cassidy, Peter Canney
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 1, 2008
Re: Should capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer?
Jim Cassidy, Hans-Joachim Schmoll, Eric Van Cutsem
Future Oncology (London, England)
|
May 20, 2009
Current status of cediranib: the rapid development of a novel anti-angiogenic therapy
Colin R Lindsay, Iain Rj MacPherson, Jim Cassidy
Page
of 5
Search research articles
Search
Showing results (11-20 of 49) with videos related to
Sort By:
Page
of 5
Expert Reviews in Molecular Medicine
|
September 25, 2004
Tumour-targeted drug and gene delivery: principles and concepts
Jim Cassidy, Andreas G Schätzlein
Expert Review of Gastroenterology & Hepatology
|
February 12, 2011
XELOX in colorectal cancer: a convenient option for the future?
Colin R Lindsay, Jim Cassidy
Seminars in Oncology
|
November 8, 2002
Oxaliplatin-related side effects: characteristics and management
Jim Cassidy, Jean-Louis Misset
Drugs
|
September 16, 2005
Adjuvant treatment strategies for early colon cancer
Ashita M Waterston, Jim Cassidy
Trials
|
April 1, 2009
The second Symptom Management Research Trial in Oncology (SMaRT Oncology-2): a randomised trial to determine the effectiveness and cost-effectiveness of adding a complex intervention for major depressive disorder to usual care for cancer patients
Jane Walker, Jim Cassidy, Michael Sharpe, et al.
Expert Opinion on Emerging Drugs
|
November 13, 2003
Emerging drugs in colorectal cancer
Lucy Scott, Judith Fraser, Jim Cassidy
Trials
|
October 2, 2009
The third symptom management research trial in oncology (SMaRT oncology-3): a randomised trial to determine the efficacy of adding a complex intervention for major depressive disorder (depression care for people with lung cancer) to usual care, compared to usual care alone in patients with lung cancer
Jane Walker, Jim Cassidy, Michael Sharpe, et al.
Cancer Treatment Reviews
|
February 15, 2005
Liver metastases from breast cancer: management of patients with significant liver dysfunction
Max S Mano, Jim Cassidy, Peter Canney
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 1, 2008
Re: Should capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer?
Jim Cassidy, Hans-Joachim Schmoll, Eric Van Cutsem
Future Oncology (London, England)
|
May 20, 2009
Current status of cediranib: the rapid development of a novel anti-angiogenic therapy
Colin R Lindsay, Iain Rj MacPherson, Jim Cassidy
Page
of 5